Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-11

Study Completion Date

2017-11-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to apply Whole-body DW imaging alongside the routine management of patients requiring systemic therapy for metastatic breast cancer to compare the time to progression of individual liver metastases within and between patients following stable disease or partial response to palliative systemic therapy for breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT02616224

Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

WITHDRAWN

Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer

NCT01392586

Metastatic Breast Cancer

TERMINATED PHASE3

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

NCT00251433

Neoplasms, Breast

TERMINATED PHASE1

Study of Stereotactic Radiotherapy for Breast Cancer

NCT03043794

Breast Cancer

TERMINATED PHASE2

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337

Metastatic Breast Cancer

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

n/a - observational

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age over 18 years.
* First metastatic breast cancer relapse after treatment for early stage disease
* A minimum of 10 evaluable lesions in the liver on routine x-ray CT imaging
* Patient prescribed cytotoxic, endocrine or biological therapies
* Patient physically and psychologically fit enough to consider sequential WB-- - DWI imaging alongside their standard disease monitoring
* Written informed consent

Exclusion Criteria

* Diagnosis of other cancer within the last 5 years, other than resected non-melanoma skin cancer or cervical intraepithelial neoplasia
* Diagnosis of brain metastases.
* Contraindication to magnetic resonance MR imaging

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No